Parabilis Medicines

Clinical-stage biopharma, formerly FogPharma, developing cell-penetrant Helicon peptides against intracellular cancer targets such as the beta-catenin pathway.

View on the globe

$975MEquity raised in 2025–20262025 — · 2026 $975M · 2 equity rounds
$1.1BEquity raised, all time3 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 3 rounds from 1 Mar 2024 to 9 Jun 2026, $1.1B equity disclosed. Earlier rounds exist but are not sourced.1 Mar 2024: Series E, $145M; 8 Jan 2026: Series F, $305M; 9 Jun 2026: IPO (Nasdaq: PBLS), $670M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 201620252026Equity round9 Jun 2026 · IPO (Nasdaq: PBLS) · $670M8 Jan 2026 · Series F · $305M · led by RA Capital Management, Fidelity, Janus Henderson Investors1 Mar 2024 · Series E · $145M · led by Nextech InvestIPO · $670MSeries F · $305MSeries E · $145M
Funding history: 3 rounds from 1 Mar 2024 to 9 Jun 2026, $1.1B equity disclosed. Earlier rounds exist but are not sourced.1 Mar 2024: Series E, $145M; 8 Jan 2026: Series F, $305M; 9 Jun 2026: IPO (Nasdaq: PBLS), $670M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’1620252026Equity round9 Jun 2026 · IPO (Nasdaq: PBLS) · $670M8 Jan 2026 · Series F · $305M · led by RA Capital Management, Fidelity, Janus Henderson Investors1 Mar 2024 · Series E · $145M · led by Nextech Invest$670M$305M$145M

Funding history 3 rounds · 7 sources · newest first

Earlier rounds not yet sourced. Parabilis Medicines was founded in 2016 and raised before 1 Mar 2024; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. IPO (Nasdaq: PBLS)
    Amount$670M
    Post-money—
    ✓ Confirmed
    Note
    Upsized IPO of 33.5M shares at $20, priced 2026-06-09 and trading from 2026-06-10, for $670M before the underwriters' 30-day option on 5M more shares. Investor Sixty Degree Capital later cited a $770M offering, consistent with full option exercise but not confirmed by the company. BioPharma Dive also reports a separate $75M private share sale to Regeneron, not recorded here.
    Sources
  2. Series F
    Amount$305M
    Post-money—
    ✓ Confirmed
    Lead
    RA Capital Management, Fidelity, Janus Henderson Investors
    Also
    Frazier Life Sciences, Soleus Capital, venBio Partners, Cormorant Asset Management, ARCH Venture Partners, GV, T. Rowe Price, Marshall Wace, General Catalyst, Foresite Capital, Samsara BioCapital, Catalio Capital Management
    Note
    Oversubscribed round at a higher valuation than the prior (early-2024, $145M) round; valuation not disclosed. The release names many more existing investors than listed here.
    Sources
  3. Series E
    Amount$145M
    Post-money—
    ✓ Confirmed
    Lead
    Nextech Invest
    Also
    RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara BioCapital, Foresite Capital, SymBiosis, Catalio Capital Management, Sixty Degree Capital, ARCH Venture Partners, Fidelity, GV, Cormorant Asset Management, T. Rowe Price, Farallon Capital Management, venBio Partners, Invus, Milky Way Investments
    Note
    Raised as FogPharma (renamed Parabilis Medicines). Company release of 2024-03-01 (Business Wire, republished by BioSpace) names the round a $145M Series E led by Nextech Invest; investors listed are the new and existing investors it names (Alex Gorsky, an individual, omitted). No 2025 round found.
    Sources
  4. Earlier rounds not yet sourced

Investors 22

  • Fidelity2
  • RA Capital Management2
  • Janus Henderson Investors1
  • Nextech Invest1
  • ARCH Venture Partners2
  • Catalio Capital Management2
  • Cormorant Asset Management2
  • Foresite Capital2
  • General Catalyst2
  • GV2
  • Marshall Wace2
  • Samsara BioCapital2
  • T. Rowe Price2
  • venBio Partners2
  • Farallon Capital Management
  • Frazier Life Sciences
  • Invus
  • Milky Way Investments
  • Rock Springs Capital
  • Sixty Degree Capital
  • Soleus Capital
  • SymBiosis

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the Cambridge hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Parabilis Medicines and its logo are trademarks of their owners, used here for identification only.